World News – UK – ViiV Healthcare and the Medicines Patent Pool are expanding access to HIV-based therapies to dolutegravir for people living with HIV in Azerbaijan, Belarus and Kazakhstan

Geneva, 30. November 2020 – ViiV Healthcare, the global HIV specialty company, majority-owned by GlaxoSmithKline plc (« GSK »), with Pfizer Inc. . and Shionogi Limited as shareholders, and the Medicines Patent Pool (MPP) announced today that it has signed a new voluntary licensing agreement to provide better access to dolutegravir (DTG) -based therapies recommended by the World Health Organization (WHO) or the United States became Department of Health and Human Services (DHHS) in certain higher middle income countries (UMICs). This new license agreement covers Azerbaijan, Belarus, Kazakhstan and Malaysia.

ViiV Healthcare and MPP recognized the unique challenges facing these countries and, in response to feedback from the HIV community and governments, developed this unique agreement to provide better access and affordability for generic DTG-based products. Treatment regimens also support continued investment in much-needed innovation. This novel agreement gives generic manufacturers the opportunity to offer DTG-based therapies at a significantly reduced price compared to the current local price, which in turn gives people with HIV better access to these drugs in every country.

Charles Gore, MPP Executive Director, said, « Improving access to life-saving medicines for low and middle income countries is at the core of our mission and we have been able to achieve this over the past 10 years through strong partnerships that include industry, Generic drug manufacturers, governments and civil society. This new and unique agreement with ViiV Healthcare, specifically aimed at improving access in these higher-middle-income countries, will result in people living with HIV in Azerbaijan, Belarus, Kazakhstan and Malaysia now having more access to affordable and from WHO-recommended dolutegravir-based treatment regimens. ”

Dr. . Meg Doherty, director of global HIV, hepatitis and STI programs at the World Health Organization, said, “WHO recommends the use of dolutegravir (DTG) as part of the preferred first-line and second-line regimen for people with HIV including pregnant women and those of childbearing age. WHO welcomes this license and, through our regional and country offices, has worked with governments and MPPs to ensure that this agreement meets the HIV treatment needs of people in these countries. ”

ViiV Healthcare and MPP will now work closely with governments and selected generic companies to make generic DTG-based therapies available in the four countries as soon as possible.

Deborah Waterhouse, CEO of ViiV Healthcare, said, “We are 100% committed to our mission not to leave people with HIV behind and are proud to have built on our existing partnership with MPP for improved access to allow dolutegravir in these upper regions. Middle-income countries according to WHO HIV treatment guidelines. Through this agreement, we have created an innovative model that enables improved access to treatment and greater affordability, while supporting continued investment in research and development of much-needed innovative drugs to achieve better long-term outcomes for people with HIV. ”

PharmiWeb. com is Europe’s leading industry-sponsored portal for the pharmaceuticals sector, providing the latest job vacancies, news, features and listings of events. The information on PharmiWeb. com is intended to support, not replace, the relationship between a patient / site visitor and their doctor.

This website is protected by reCAPTCHA and the Google privacy policy and terms of use apply.

follow us

Copyright © 2020 PHARMIWEB. COM LIMITED, rights reserved by their respective owners.

Disclaimer: You are now leaving PharmiWeb. com website and go to a website that is not operated by us. We are not responsible for the content or availability of linked sites.

PharmiWeb. com offers links to other third-party websites that may be of interest to visitors to our website. The links provided on our website are for your convenience only and may help you find other useful information on the Internet. If you click on these links, you leave the PharmiWeb. com website and will be redirected to another website. These websites are not under the control of PharmiWeb. com.

PharmiWeb. com is not responsible for the content of linked third party websites. We are neither a representative of these third parties nor do we endorse or guarantee their products. We do not give any representation or guarantee with regard to the correctness of the information contained on the linked sites. We recommend that you always review the information received from any linked website before responding to that information.

Please also note that the security and data protection guidelines on these websites may differ from those of PharmiWeb. Please read the third-party privacy and security guidelines carefully.

If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.

Dolutegravir, HIV, HIV / AIDS, ViiV Healthcare Limited, Healthcare, World Health Organization